AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage.
Instead of adding the trial to an ongoing US process, AstraZeneca might launch a fresh study to evaluate a lower dosage of its vaccine that performed better than a full dosage.
The news comes as AstraZeneca faces questions about its success rate that some experts say could hinder its chances of getting speedy US and EU regulatory approval.
Watch the video.
